Is Buying Nike Stock Now a Brilliant Move or a Disaster Waiting to Happen? Here's the Answer and What to Do Next.

Nike’s fiscal 2027 first-quarter EPS of $0.48 beat the $0.43 estimate, but revenue of $11.2 billion missed the $11.3 billion estimate. The company expects full-year revenue to decline by a high-single-digit percentage and is pursuing restructuring expected to result in job cuts, amid weakness in Greater China, Sportswear and Jordan; the article says shares fell 55% over the past 12 months. The author recommends waiting for sustained beats and improved forecasts, while noting Johnson & Johnson shares gained 38% over 12 months and Sirius XM raised its 2026 forecasts.

Analysis

Nike’s risk is not simply a weak quarter: if demand and product relevance are the binding constraints, restructuring can improve reported costs before it improves sell-through. That creates a risk of superficially steadier EPS alongside continued revenue pressure; cuts that constrain design, marketing, or retail execution could also slow recovery. If Nike continues to concede shelf space or full-price demand, Adidas, Deckers, and other athletic-apparel competitors may benefit, but share gains should be verified rather than assumed.

Near term, restructuring charges and further guidance changes can keep sentiment fragile. Over 1–3 months, watch full-price sell-through, inventory/promotion levels, and regional and brand-level trends—not headcount announcements—as evidence of demand repair. Over 6–18 months, sustained product traction and restored growth would matter more than cost savings. A sharp improvement in those indicators, or guidance stabilization, would challenge the bearish view; another forecast reduction or evidence of heavier discounting would strengthen it.

JNJ and SIRI are not clean substitutes for Nike exposure: their drivers differ, and the article’s positive framing does not establish relative value. SIRI’s reported listener additions and forecast changes need follow-through in subscriber trends and free cash flow; JNJ’s portfolio focus does not remove drug-development, patent, or regulatory risks. The contrarian opportunity in Nike is a potential recovery after a large decline, but price weakness alone is not a catalyst.

Key Decisions for Investors

• Keep NKE underweight rather than treating the share-price decline as a buy signal. Reassess after consecutive quarters of improving sell-through and stable guidance; treat expense reductions without demand improvement as low-quality progress.
• For a bearish expression, consider a defined-risk 3–6 month NKE put spread only if option pricing is reasonable and the position is sized for a sharp relief rally. Avoid an outright short if improving product demand or guidance stabilization would invalidate the thesis.
• Track Adidas and Deckers as potential share-gain beneficiaries, but require evidence in relative sell-through, inventory, or management commentary before initiating a paired trade against NKE.
• Do not rotate into JNJ or SIRI solely as turnaround alternatives. For SIRI, verify that net additions persist and translate into free cash flow; for JNJ, underwrite its own pipeline and patent risks independently.